A Chinese scientist, Jiankui He, and his creation of the world ' s first genetically altered baby made headlines recently. As a newly developed gene-editing technique, the CRISPR/Cas system should not be applied t...A Chinese scientist, Jiankui He, and his creation of the world ' s first genetically altered baby made headlines recently. As a newly developed gene-editing technique, the CRISPR/Cas system should not be applied to human beings for reproductive purposes until it has been extensively tested. However, numerous experimental research studies in human somatic, germline cells, and even in embryos, have been conducted, which have shown CRISPR/Cas to be a useful tool for human genome editing and a potential therapeutic method for future clinical use.展开更多
2015年4月我国英文学术期刊《蛋白质与细胞》(Potein and Cell)发表了中山大学黄军就副教授关于利用CRISPR/Cas9基因编辑技术对人类胚胎中地中海贫血症致病基因修饰的研究成果,引起了国内外对基因编辑技术及其应用研究的大讨论。本文简...2015年4月我国英文学术期刊《蛋白质与细胞》(Potein and Cell)发表了中山大学黄军就副教授关于利用CRISPR/Cas9基因编辑技术对人类胚胎中地中海贫血症致病基因修饰的研究成果,引起了国内外对基因编辑技术及其应用研究的大讨论。本文简要介绍了几种不同的基因组编辑技术的原理,比较分析了它们的优缺点。由于ZFNs和TALENs相对低效有更容易发生脱靶等缺点,而NgAgo基因编辑技术在几个月之前刚刚发表,目前的研究文献不多,因此本文主要总结了CRISPR/Cas基因编辑技术的研究进展,对其疾病基因治疗的应用前景进行了展望,同时对涉及的伦理和相关法规建设问题进行了分析并对监管机构制定政策提出了有益建议。展开更多
基金National Key Research and Development Program of China,Grant/Award Number:2016YFA0100103CAMS Innovation Fund for Medical Sciences,Grant/Award Number:2016-I2M-3-002
文摘A Chinese scientist, Jiankui He, and his creation of the world ' s first genetically altered baby made headlines recently. As a newly developed gene-editing technique, the CRISPR/Cas system should not be applied to human beings for reproductive purposes until it has been extensively tested. However, numerous experimental research studies in human somatic, germline cells, and even in embryos, have been conducted, which have shown CRISPR/Cas to be a useful tool for human genome editing and a potential therapeutic method for future clinical use.
文摘2015年4月我国英文学术期刊《蛋白质与细胞》(Potein and Cell)发表了中山大学黄军就副教授关于利用CRISPR/Cas9基因编辑技术对人类胚胎中地中海贫血症致病基因修饰的研究成果,引起了国内外对基因编辑技术及其应用研究的大讨论。本文简要介绍了几种不同的基因组编辑技术的原理,比较分析了它们的优缺点。由于ZFNs和TALENs相对低效有更容易发生脱靶等缺点,而NgAgo基因编辑技术在几个月之前刚刚发表,目前的研究文献不多,因此本文主要总结了CRISPR/Cas基因编辑技术的研究进展,对其疾病基因治疗的应用前景进行了展望,同时对涉及的伦理和相关法规建设问题进行了分析并对监管机构制定政策提出了有益建议。